Procter & Gamble Health Limited (PGHL.NS)
INR 5467.25
(0.04%)
INR 5467.25
(0.04%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 68.8 Million INR | -22.52% |
| 2022 | 88.8 Million INR | 0.0% |
| 2021 | - INR | -100.0% |
| 2020 | 28.6 Million INR | 0.0% |
| 2019 | - INR | 0.0% |
| 2018 | - INR | 0.0% |
| 2017 | - INR | 0.0% |
| 2016 | - INR | 0.0% |
| 2015 | - INR | 0.0% |
| 2014 | - INR | 0.0% |
| 2013 | - INR | 0.0% |
| 2012 | - INR | 0.0% |
| 2011 | - INR | 0.0% |
| 2010 | - INR | 0.0% |
| 2009 | - INR | 0.0% |
| 2008 | - INR | 0.0% |
| 2007 | - INR | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 FY | 68.8 Million INR | -22.52% |
| 2023 Q4 | 68.8 Million INR | 0.0% |
| 2023 Q1 | - INR | -100.0% |
| 2023 Q2 | 80.3 Million INR | 0.0% |
| 2023 Q3 | - INR | -100.0% |
| 2022 Q1 | - INR | 0.0% |
| 2022 FY | 88.8 Million INR | 0.0% |
| 2022 Q3 | - INR | -100.0% |
| 2022 Q4 | 88.8 Million INR | 0.0% |
| 2022 Q2 | 106.8 Million INR | 0.0% |
| 2021 Q4 | - INR | 0.0% |
| 2021 Q3 | - INR | -100.0% |
| 2021 Q2 | 2.9 Million INR | 0.0% |
| 2021 FY | - INR | -100.0% |
| 2021 Q1 | - INR | -100.0% |
| 2020 Q2 | 95.2 Million INR | 0.0% |
| 2020 Q3 | - INR | -100.0% |
| 2020 Q4 | 28.6 Million INR | 0.0% |
| 2020 FY | 28.6 Million INR | 0.0% |
| 2020 Q1 | - INR | 0.0% |
| 2019 Q4 | - INR | 0.0% |
| 2019 FY | - INR | 0.0% |
| 2019 Q1 | - INR | 0.0% |
| 2018 Q1 | - INR | 0.0% |
| 2018 FY | - INR | 0.0% |
| 2018 Q2 | - INR | 0.0% |
| 2018 Q4 | - INR | 0.0% |
| 2018 Q3 | - INR | 0.0% |
| 2017 Q1 | - INR | 0.0% |
| 2017 FY | - INR | 0.0% |
| 2017 Q4 | - INR | 0.0% |
| 2017 Q2 | - INR | 0.0% |
| 2017 Q3 | - INR | 0.0% |
| 2016 Q3 | - INR | 0.0% |
| 2016 Q4 | - INR | 0.0% |
| 2016 FY | - INR | 0.0% |
| 2016 Q2 | - INR | 0.0% |
| 2015 FY | - INR | 0.0% |
| 2015 Q4 | - INR | 0.0% |
| 2015 Q3 | - INR | 0.0% |
| 2015 Q2 | - INR | 0.0% |
| 2015 Q1 | - INR | 0.0% |
| 2014 Q3 | - INR | 0.0% |
| 2014 Q2 | - INR | 0.0% |
| 2014 Q1 | - INR | 0.0% |
| 2014 FY | - INR | 0.0% |
| 2014 Q4 | - INR | 0.0% |
| 2013 Q3 | - INR | 0.0% |
| 2013 Q1 | - INR | 0.0% |
| 2013 FY | - INR | 0.0% |
| 2013 Q2 | - INR | 0.0% |
| 2013 Q4 | - INR | 0.0% |
| 2012 FY | - INR | 0.0% |
| 2012 Q2 | - INR | 0.0% |
| 2012 Q3 | - INR | 0.0% |
| 2012 Q4 | - INR | 0.0% |
| 2011 FY | - INR | 0.0% |
| 2011 Q2 | - INR | 0.0% |
| 2011 Q4 | - INR | 0.0% |
| 2010 FY | - INR | 0.0% |
| 2009 FY | - INR | 0.0% |
| 2008 FY | - INR | 0.0% |
| 2007 FY | - INR | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| Sigachi Industries Limited | 265.79 Million INR | 74.116% |
| Ind-Swift Limited | 10.09 Billion INR | 99.318% |
| Bajaj HealthCare Limited | 650.34 Million INR | 89.421% |
| Sakar Healthcare Limited | 549.55 Million INR | 87.481% |
| Aurobindo Pharma Limited | 21.34 Billion INR | 99.678% |
| Innova Captab Limited | 2.1 Billion INR | 96.732% |
| Divi's Laboratories Limited | 20 Million INR | -244.0% |
| AstraZeneca Pharma India Limited | 27.83 Million INR | -147.162% |
| Morepen Laboratories Limited | 33.64 Million INR | -104.518% |
| Mankind Pharma Limited | 325.81 Million INR | 78.884% |
| Sequent Scientific Limited | 1.42 Billion INR | 95.179% |
| Wanbury Limited | 820 Million INR | 91.61% |
| Laurus Labs Limited | 7.98 Billion INR | 99.138% |
| Nectar Lifesciences Limited | 1.4 Billion INR | 95.097% |
| Glenmark Life Sciences Limited | 147.61 Million INR | 53.391% |
| Alembic Limited | 73.9 Million INR | 6.901% |
| Hikal Limited | 4.22 Billion INR | 98.373% |
| Alembic Pharmaceuticals Limited | 628.8 Million INR | 89.059% |
| Neuland Laboratories Limited | 449.2 Million INR | 84.684% |
| J. B. Chemicals & Pharmaceuticals Limited | 236.4 Million INR | 70.897% |
| Glenmark Pharmaceuticals Limited | 1.51 Billion INR | 95.464% |
| IOL Chemicals and Pharmaceuticals Limited | - INR | -Infinity% |
| Themis Medicare Limited | 267.74 Million INR | 74.303% |
| RPG Life Sciences Limited | -30.3 Million INR | 327.063% |
| Zydus Lifesciences Limited | 251 Million INR | 72.59% |
| Lupin Limited | 1.55 Billion INR | 95.569% |
| Amrutanjan Health Care Limited | 13.96 Million INR | -392.554% |
| Wockhardt Limited | 8.91 Billion INR | 99.228% |
| Vaishali Pharma Limited | 35.98 Million INR | -91.201% |
| Aarti Pharmalabs Limited | 400 Thousand INR | -17100.0% |
| Jagsonpal Pharmaceuticals Limited | 75.57 Million INR | 8.959% |
| Jubilant Pharmova Limited | 31.67 Billion INR | 99.783% |
| FDC Limited | 2.46 Million INR | -2689.943% |
| Dr. Reddy's Laboratories Limited | 5.99 Billion INR | 98.851% |
| Kilitch Drugs (India) Limited | - INR | -Infinity% |
| Eris Lifesciences Limited | 6.54 Billion INR | 98.949% |
| Venus Remedies Limited | 386.8 Million INR | 82.213% |
| ZIM Laboratories Limited | 356 Million INR | 80.674% |
| Bliss GVS Pharma Limited | 355.92 Million INR | 80.67% |
| Par Drugs and Chemicals Limited | - INR | -Infinity% |
| Caplin Point Laboratories Limited | 9.2 Million INR | -647.826% |
| Shilpa Medicare Limited | 5.6 Billion INR | 98.772% |
| Albert David Limited | 6.01 Million INR | -1043.617% |
| Ajanta Pharma Limited | 235.2 Million INR | 70.748% |
| Hester Biosciences Limited | 1.81 Billion INR | 96.215% |
| Suven Pharmaceuticals Limited | 212.35 Million INR | 67.602% |
| Solara Active Pharma Sciences Limited | 1.17 Billion INR | 94.142% |
| Gufic Biosciences Limited | 1.53 Billion INR | 95.531% |
| Windlas Biotech Limited | 20.18 Million INR | -240.932% |
| Aarey Drugs & Pharmaceuticals Limited | 32.24 Million INR | -113.375% |
| Mangalam Drugs & Organics Limited | 133.54 Million INR | 48.48% |
| Granules India Limited | 689.71 Million INR | 90.025% |
| Aarti Drugs Limited | 2.75 Billion INR | 97.501% |
| Bal Pharma Limited | 363.82 Million INR | 81.09% |
| Alkem Laboratories Limited | 400 Million INR | 82.8% |
| Sun Pharmaceutical Industries Limited | 13.3 Million INR | -417.293% |
| Lincoln Pharmaceuticals Limited | - INR | -Infinity% |
| Medicamen Biotech Limited | 12.55 Million INR | -447.989% |
| Unichem Laboratories Limited | 382.22 Million INR | 82.0% |
| Bafna Pharmaceuticals Limited | 107.53 Million INR | 36.019% |
| Biofil Chemicals and Pharmaceuticals Limited | - INR | -Infinity% |
| Valiant Laboratories Limited | 750.89 Million INR | 90.838% |
| Orchid Pharma Limited | 1.2 Billion INR | 94.287% |
| Medico Remedies Limited | 8.67 Million INR | -693.358% |
| Ind-Swift Laboratories Limited | 111.62 Million INR | 38.366% |
| Ipca Laboratories Limited | 5.8 Billion INR | 98.815% |
| Brooks Laboratories Limited | 3.56 Million INR | -1829.874% |
| Syncom Formulations (India) Limited | -1.21 Million INR | 5743.97% |
| Piramal Enterprises Limited | 535.85 Billion INR | 99.987% |
| Torrent Pharmaceuticals Limited | 16.04 Billion INR | 99.571% |
| NATCO Pharma Limited | 53 Million INR | -29.811% |
| Suven Life Sciences Limited | - INR | -Infinity% |
| Krebs Biochemicals & Industries Limited | 1.83 Billion INR | 96.251% |
| Strides Pharma Science Limited | 6.71 Billion INR | 98.975% |
| Indoco Remedies Limited | 3.51 Billion INR | 98.044% |
| Alpa Laboratories Limited | - INR | -Infinity% |
| Lasa Supergenerics Limited | - INR | -Infinity% |
| Sun Pharma Advanced Research Company Limited | 106.6 Million INR | 35.46% |